Related Experiment Video
Updated: Feb 16, 2026

Detection of miRNA Targets in High-throughput Using the 3'LIFE Assay
Published on: May 25, 2015
Cancer immunotherapy-targeted glypican-3 or neoantigens
Yasuhiro Shimizu1,2, Toshihiro Suzuki1, Toshiaki Yoshikawa1
1Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Abstract:
Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.
Insights
Glypican-3 peptide vaccines show promise in cancer immunotherapy by inducing specific CTLs in most patients. This approach, alongside neoantigen-based personalized therapy, offers potential for cancer regression and future treatment advancements.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
- There remains a need for alternative and combination therapies for patients unresponsive to current treatments.
Purpose of the Study:
- To evaluate the efficacy of glypican-3 peptide vaccines in inducing specific CTLs.
- To assess the potential of personalized cancer immunotherapy based on neoantigens for cancer regression.
Main Methods:
- Clinical trials were conducted to assess glypican-3 peptide vaccines.
- Analysis of patient immune responses, including the induction of specific CTLs.
- Review of current personalized cancer immunotherapy strategies.
Main Results:
- Glypican-3 peptide vaccines successfully induced specific CTLs in the majority of patients.
- Evidence suggests the potential of glypican-3 peptide vaccines in cancer treatment.
Conclusions:
- Glypican-3 peptide vaccines are a promising avenue for cancer immunotherapy.
- Personalized immunotherapy based on neoantigens holds potential for inducing cancer regression.
- Further research into novel cancer immunotherapies is warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

